The vast majority of men who try to have a family following treatment for testicular cancer are able to father children, according to a report published in the British Journal of Cancer
Scientists at the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust studied almost 700 patients who had been treated for testicular cancer between 1982 and 1992 and asked them to complete a questionnaire relating to fertility and general health.
Just over 200 men reported attempting conception and 159 of these (77%) succeeded in becoming fathers.
A further ten patients fathered children after fertility treatment.
The study also found that patients treated with chemotherapy after surgery had an increased risk of infertility compared to those who had no follow-up treatment or had radiotherapy only.
But it was less than had been expected.
Among the men attempting conception without fertility treatment, those who had had surgery but no further treatment had the highest rate of success (85%); those who had radiotherapy achieved an 82% success rate; those who had chemotherapy achieved a 71% success rate, and those who were given both chemotherapy and radiotherapy had a 67% success rate.
Lead scientist Robert Huddart of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, says: "Our previous studies suggested that most men's sperm counts recover after chemotherapy.
"In this study we have shown that after treatment with chemotherapy or radiotherapy the majority of men who want to father children can do so.
"In patients who had no treatment after surgery we found that 15% had difficulty conceiving; treatment made this percentage slightly higher but not dramatically so.
"More than 70% of patients who had chemotherapy were still fertile.
"It is important that patients should be monitored for testosterone as low levels of this hormone affect quality of life and men with less testosterone tend to be less sexually active".
Patients were also invited to answer questions about sexual function and satisfaction.
Most men answered this and of those more than 83% said they had a satisfying sexual relationship with their partner.
Peter Rigby, chief executive of the Institute of Cancer Research, says: "This is very encouraging news; testicular cancer is the most common cancer in young men, many of whom are likely to hope to go on and have children following treatment.
"The study also highlights the great progress in cancer treatment, not only is testicular cancer 99% curable if it is caught early enough, but the vast majority of men can go on to lead normal lives following treatment".
John Toy, medical director of Cancer Research UK - which owns the British Journal of Cancer and partly funded the study - said: "This study is particularly heartening for young men diagnosed with testicular cancer and for their partners.
"It goes a long way towards allaying the natural fears that treatment will leave them unable to have children".
Around 2000 cases of testicular cancer are registered in the UK each year.
More than 95% of cases are curable.
Around half of all cases are in men aged under 35.
The disease rarely occurs before puberty but it is the most common cancer in men aged 15-44 years.
The Institute of Cancer Research claims to be is Europe's leading cancer research centre with expert scientists working on cutting edge research.
It was founded in 1909 to carry out research into the causes of cancer and to develop new strategies for its prevention, diagnosis, treatment and care.
The Everyman Centre, at the Institute of Cancer Research, is Europe's first and only dedicated male cancer research centre.
Everyman is the Institute of Cancer Research's campaign to raise awareness of and funding for male cancer.
Everyman must raise £1.5 million each year to support the vital research into male cancer conducted at the centre.
The Institute works in a unique partnership with the Royal Marsden NHS Foundation Trust, forming what is said to be the largest comprehensive cancer centre in Europe.
The Royal Marsden NHS Foundation Trust is a leader in the field of cancer, with a successful record of innovation in nursing care, pioneering new treatments and the development of anti-cancer drugs.
